<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00960791</url>
  </required_header>
  <id_info>
    <org_study_id>D1020C00008</org_study_id>
    <nct_id>NCT00960791</nct_id>
  </id_info>
  <brief_title>Study to Assess the Absorption, Distribution, Metabolism and Excretion of AZD1656 in Type 2 Diabetes Mellitus (T2DM)</brief_title>
  <acronym>ADME</acronym>
  <official_title>An Open, Single-centre, Single Group, Phase I Study to Assess the Absorption, Distribution, Metabolism and Excretion (ADME) of AZD1656 After Oral Administration of 14C-labelled AZD1656 to Type II Diabetes Mellitus Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <brief_summary>
    <textblock>
      The purpose of the study is to evaluate the absorption, distribution, metabolism and
      excretion of AZD1656 after administration of a single oral dose of 14C-labelled AZD1656
      solution in male Type 2 Diabetes Mellitus patients.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2009</start_date>
  <completion_date type="Actual">September 2009</completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Total recovery of radioactive dose, rate and routes of excretion of total radioactivity, metabolic pattern and metabolic profile, and PK variables of AZD1656 (AUC, Cmax, tmax, t1/2, Total Ae, CL/F and CLR)</measure>
    <time_frame>One blood sample for analysis of plasma concentrations of AZD1656 taken on several days during the treatment period. A full PK profile for AZD1656 will also be taken on the last day of treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety variables: Adverse Events (AEs), Blood pressure (BP), pulse, ECG and safety laboratory variables, glucose quick test</measure>
    <time_frame>Frequent measurements during the study period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Glucose</measure>
    <time_frame>Plasma Glucose will be measured twice daily during residential period</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">6</enrollment>
  <condition>Type II Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>14C-labelled AZD1656</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>AZD1656</intervention_name>
    <description>Oral single dose</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male type II diabetes patients diagnosed for more than 5 years and aged between 35 and
             65 years.

          -  Subjects treated with metformin alone or metformin and one other oral anti-diabetic
             drug.

          -  Subjects should have FPG in the range of 6.0 to 11.0 mmol/L at screening and HbA1c
             less than 10% (HbA1c value according to international DCCT standard).

        Exclusion Criteria:

          -  History of ischemic heart disease, stroke, transient ischemic attack or symptomatic
             peripheral vascular disease.

          -  Renal dysfunction.

          -  Use of insulin, glitazones, warfarin and amiodarone within 3 months before enrolment
             and use of potent CYP450 inhibitors, e.g., ketoconazole and macrolide antibiotics
             within 14 days before administration of IP.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Klas Malmberg, MD, PhD, Prof.,</last_name>
    <role>Study Director</role>
    <affiliation>AstraZeneca R&amp;D Mölndal, SE-431 83 Mölndal, Sweden</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Emeline Ramos, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Clinical Pharmacology Unit (CPU)AstraZeneca R&amp;D Alderley ParkMacclesfield, Cheshire SK10 4TG, UK</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 17, 2009</study_first_submitted>
  <study_first_submitted_qc>August 17, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 18, 2009</study_first_posted>
  <last_update_submitted>September 15, 2009</last_update_submitted>
  <last_update_submitted_qc>September 15, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 16, 2009</last_update_posted>
  <responsible_party>
    <name_title>MSD</name_title>
    <organization>AstraZeneca</organization>
  </responsible_party>
  <keyword>Type II diabetes mellitus</keyword>
  <keyword>absorption</keyword>
  <keyword>distribution</keyword>
  <keyword>metabolism</keyword>
  <keyword>excretion</keyword>
  <keyword>14C-labelled</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

